ID   E2AK3_HUMAN             Reviewed;        1116 AA.
AC   Q9NZJ5; A0AVH1; A0AVH2; B2RCU9; O95846; Q53QY0; Q53SB1;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   12-OCT-2022, entry version 207.
DE   RecName: Full=Eukaryotic translation initiation factor 2-alpha kinase 3;
DE            EC=2.7.11.1;
DE   AltName: Full=PRKR-like endoplasmic reticulum kinase;
DE   AltName: Full=Pancreatic eIF2-alpha kinase;
DE            Short=HsPEK;
DE   Flags: Precursor;
GN   Name=EIF2AK3; Synonyms=PEK, PERK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND VARIANTS ARG-166 AND
RP   SER-704.
RC   TISSUE=Liver, Pancreas, and Testis;
RX   PubMed=10026192; DOI=10.1074/jbc.274.9.5723;
RA   Shi Y., An J., Liang J., Hayes S.E., Sandusky G.E., Stramm L.E., Yang N.N.;
RT   "Characterization of a mutant pancreatic eIF-2alpha kinase, PEK, and co-
RT   localization with somatostatin in islet delta cells.";
RL   J. Biol. Chem. 274:5723-5730(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHARACTERIZATION, AND VARIANTS ARG-166 AND
RP   SER-704.
RC   TISSUE=Brain, and Pancreas;
RX   PubMed=10677345; DOI=10.1042/bj3460281;
RA   Sood R., Porter A.C., Ma K., Quilliam L.A., Wek R.C.;
RT   "Pancreatic eukaryotic initiation factor-2alpha kinase (PEK) homologues in
RT   humans, Drosophila melanogaster and Caenorhabditis elegans that mediate
RT   translational control in response to endoplasmic reticulum stress.";
RL   Biochem. J. 346:281-293(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT WRS GLN-588, AND VARIANT
RP   CYS-136.
RX   PubMed=10932183; DOI=10.1038/78085;
RA   Delepine M., Nicolino M., Barrett T., Golamaully M., Lathrop G.M.,
RA   Julier C.;
RT   "EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is
RT   mutated in patients with Wolcott-Rallison syndrome.";
RL   Nat. Genet. 25:406-409(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-166 AND SER-704.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-715, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [8]
RP   PHOSPHORYLATION AT TYR-619, AND DEPHOSPHORYLATION AT TYR-619.
RX   PubMed=22169477; DOI=10.1126/scisignal.2002329;
RA   Krishnan N., Fu C., Pappin D.J., Tonks N.K.;
RT   "H2s-induced sulfhydration of the phosphatase PTP1B and its role in the
RT   endoplasmic reticulum stress response.";
RL   Sci. Signal. 4:RA86-RA86(2011).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1094, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [10]
RP   ADP-RIBOSYLATION BY PARP16.
RX   PubMed=23103912; DOI=10.1038/ncb2593;
RA   Jwa M., Chang P.;
RT   "PARP16 is a tail-anchored endoplasmic reticulum protein required for the
RT   PERK-and IRE1alpha-mediated unfolded protein response.";
RL   Nat. Cell Biol. 14:1223-1230(2012).
RN   [11]
RP   INTERACTION WITH PDIA6.
RX   PubMed=24508390; DOI=10.1016/j.molcel.2014.01.004;
RA   Eletto D., Eletto D., Dersh D., Gidalevitz T., Argon Y.;
RT   "Protein disulfide isomerase A6 controls the decay of IRE1alpha signaling
RT   via disulfide-dependent association.";
RL   Mol. Cell 53:562-576(2014).
RN   [12]
RP   INTERACTION WITH TMEM33.
RX   PubMed=26268696; DOI=10.1007/s10549-015-3536-7;
RA   Sakabe I., Hu R., Jin L., Clarke R., Kasid U.N.;
RT   "TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein
RT   and modulator of the unfolded protein response signaling.";
RL   Breast Cancer Res. Treat. 153:285-297(2015).
RN   [13]
RP   INTERACTION WITH LACC1.
RX   PubMed=31875558; DOI=10.1016/j.celrep.2019.11.105;
RA   Huang C., Hedl M., Ranjan K., Abraham C.;
RT   "LACC1 required for NOD2-induced, ER stress-mediated innate immune outcomes
RT   in human macrophages and LACC1 risk variants modulate these outcomes.";
RL   Cell Rep. 29:4525-4539(2019).
RN   [14]
RP   FUNCTION.
RX   PubMed=33384352; DOI=10.1126/science.abb6896;
RA   You K., Wang L., Chou C.H., Liu K., Nakata T., Jaiswal A., Yao J.,
RA   Lefkovith A., Omar A., Perrigoue J.G., Towne J.E., Regev A., Graham D.B.,
RA   Xavier R.J.;
RT   "QRICH1 dictates the outcome of ER stress through transcriptional control
RT   of proteostasis.";
RL   Science 371:0-0(2021).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-136; VAL-566 AND LEU-716.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Metabolic-stress sensing protein kinase that phosphorylates
CC       the alpha subunit of eukaryotic translation initiation factor 2
CC       (EIF2S1/eIF-2-alpha) in response to various stress conditions. Key
CC       activator of the integrated stress response (ISR) required for
CC       adaptation to various stress, such as unfolded protein response (UPR)
CC       and low amino acid availability (By similarity). EIF2S1/eIF-2-alpha
CC       phosphorylation in response to stress converts EIF2S1/eIF-2-alpha in a
CC       global protein synthesis inhibitor, leading to a global attenuation of
CC       cap-dependent translation, while concomitantly initiating the
CC       preferential translation of ISR-specific mRNAs, such as the
CC       transcriptional activators ATF4 and QRICH1, and hence allowing
CC       ATF4- and QRICH1-mediated reprogramming (PubMed:33384352). Serves as a
CC       critical effector of unfolded protein response (UPR)-induced G1 growth
CC       arrest due to the loss of cyclin-D1 (CCND1). Involved in control of
CC       mitochondrial morphology and function (By similarity).
CC       {ECO:0000250|UniProtKB:Q9Z2B5, ECO:0000269|PubMed:33384352}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Perturbation in protein folding in the endoplasmic
CC       reticulum (ER) promotes reversible dissociation from HSPA5/BIP and
CC       oligomerization, resulting in transautophosphorylation and kinase
CC       activity induction. {ECO:0000250|UniProtKB:Q9Z2B5}.
CC   -!- SUBUNIT: Forms dimers with HSPA5/BIP in resting cells (By similarity).
CC       Oligomerizes in ER-stressed cells (By similarity). Interacts with
CC       DNAJC3 and MFN2 (By similarity). Interacts with TMEM33
CC       (PubMed:26268696). Interacts with PDIA6 (PubMed:24508390). Interacts
CC       with LACC1 (PubMed:31875558). {ECO:0000250|UniProtKB:Q9Z2B5,
CC       ECO:0000269|PubMed:24508390, ECO:0000269|PubMed:26268696,
CC       ECO:0000269|PubMed:31875558}.
CC   -!- INTERACTION:
CC       Q9NZJ5; Q9NZJ5: EIF2AK3; NbExp=2; IntAct=EBI-766076, EBI-766076;
CC       Q9NZJ5; P11021: HSPA5; NbExp=4; IntAct=EBI-766076, EBI-354921;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Single-pass type
CC       I membrane protein.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. A high level expression is seen in
CC       secretory tissues.
CC   -!- INDUCTION: By endoplasmic reticulum stress.
CC   -!- DOMAIN: The lumenal domain senses perturbations in protein folding in
CC       the ER, probably through reversible interaction with HSPA5/BIP.
CC       {ECO:0000250}.
CC   -!- PTM: Oligomerization of the N-terminal ER luminal domain by ER stress
CC       promotes PERK trans-autophosphorylation of the C-terminal cytoplasmic
CC       kinase domain at multiple residues including Thr-982 on the kinase
CC       activation loop (By similarity). Autophosphorylated. Phosphorylated at
CC       Tyr-619 following endoplasmic reticulum stress, leading to activate its
CC       tyrosine-protein kinase activity. Dephosphorylated by PTPN1/TP1B,
CC       leading to inactivate its enzyme activity. {ECO:0000250,
CC       ECO:0000269|PubMed:22169477}.
CC   -!- PTM: N-glycosylated. {ECO:0000250}.
CC   -!- PTM: ADP-ribosylated by PARP16 upon ER stress, which increases kinase
CC       activity.
CC   -!- DISEASE: Wolcott-Rallison syndrome (WRS) [MIM:226980]: A rare autosomal
CC       recessive disorder, characterized by permanent neonatal or early
CC       infancy insulin-dependent diabetes and, at a later age, epiphyseal
CC       dysplasia, osteoporosis, growth retardation and other multisystem
CC       manifestations, such as hepatic and renal dysfunctions, intellectual
CC       disability and cardiovascular abnormalities.
CC       {ECO:0000269|PubMed:10932183}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. GCN2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF110146; AAD19961.1; -; mRNA.
DR   EMBL; AF193339; AAF61199.1; -; mRNA.
DR   EMBL; AF284615; AAF91480.1; -; Genomic_DNA.
DR   EMBL; AF284604; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AF284605; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AF284606; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AF284607; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AF284608; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AF284609; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AF284610; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AF284611; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AF284612; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AF284613; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AF284614; AAF91480.1; JOINED; Genomic_DNA.
DR   EMBL; AK315287; BAG37696.1; -; mRNA.
DR   EMBL; AC062029; AAY14777.1; -; Genomic_DNA.
DR   EMBL; AC104134; AAY24331.1; -; Genomic_DNA.
DR   EMBL; BC126354; AAI26355.1; -; mRNA.
DR   EMBL; BC126356; AAI26357.1; -; mRNA.
DR   CCDS; CCDS33241.1; -.
DR   RefSeq; NP_004827.4; NM_004836.6.
DR   PDB; 4G31; X-ray; 2.28 A; A=588-1093.
DR   PDB; 4G34; X-ray; 2.70 A; A=588-1093.
DR   PDB; 4M7I; X-ray; 2.34 A; A=588-1093.
DR   PDB; 4X7H; X-ray; 2.00 A; A=575-1094.
DR   PDB; 4X7J; X-ray; 2.30 A; A=575-1094.
DR   PDB; 4X7K; X-ray; 1.80 A; A=575-1094.
DR   PDB; 4X7L; X-ray; 1.90 A; A=575-1094.
DR   PDB; 4X7N; X-ray; 2.35 A; A=575-1094.
DR   PDB; 4X7O; X-ray; 2.65 A; A=575-1094.
DR   PDB; 4YZS; X-ray; 3.14 A; A/B=104-403.
DR   PDB; 5SV7; X-ray; 3.21 A; A/B/C/D=95-420.
DR   PDB; 7MF0; X-ray; 2.81 A; AAA=575-1094.
DR   PDBsum; 4G31; -.
DR   PDBsum; 4G34; -.
DR   PDBsum; 4M7I; -.
DR   PDBsum; 4X7H; -.
DR   PDBsum; 4X7J; -.
DR   PDBsum; 4X7K; -.
DR   PDBsum; 4X7L; -.
DR   PDBsum; 4X7N; -.
DR   PDBsum; 4X7O; -.
DR   PDBsum; 4YZS; -.
DR   PDBsum; 5SV7; -.
DR   PDBsum; 7MF0; -.
DR   AlphaFoldDB; Q9NZJ5; -.
DR   SMR; Q9NZJ5; -.
DR   BioGRID; 114840; 157.
DR   IntAct; Q9NZJ5; 41.
DR   MINT; Q9NZJ5; -.
DR   STRING; 9606.ENSP00000307235; -.
DR   BindingDB; Q9NZJ5; -.
DR   ChEMBL; CHEMBL6030; -.
DR   GuidetoPHARMACOLOGY; 2017; -.
DR   GlyGen; Q9NZJ5; 2 sites.
DR   iPTMnet; Q9NZJ5; -.
DR   PhosphoSitePlus; Q9NZJ5; -.
DR   BioMuta; EIF2AK3; -.
DR   DMDM; 296439367; -.
DR   EPD; Q9NZJ5; -.
DR   jPOST; Q9NZJ5; -.
DR   MassIVE; Q9NZJ5; -.
DR   MaxQB; Q9NZJ5; -.
DR   PaxDb; Q9NZJ5; -.
DR   PeptideAtlas; Q9NZJ5; -.
DR   PRIDE; Q9NZJ5; -.
DR   ProteomicsDB; 83416; -.
DR   Antibodypedia; 2635; 645 antibodies from 38 providers.
DR   DNASU; 9451; -.
DR   Ensembl; ENST00000303236.9; ENSP00000307235.3; ENSG00000172071.15.
DR   GeneID; 9451; -.
DR   KEGG; hsa:9451; -.
DR   MANE-Select; ENST00000303236.9; ENSP00000307235.3; NM_004836.7; NP_004827.4.
DR   UCSC; uc002stc.5; human.
DR   CTD; 9451; -.
DR   DisGeNET; 9451; -.
DR   GeneCards; EIF2AK3; -.
DR   HGNC; HGNC:3255; EIF2AK3.
DR   HPA; ENSG00000172071; Tissue enhanced (pancreas).
DR   MalaCards; EIF2AK3; -.
DR   MIM; 226980; phenotype.
DR   MIM; 604032; gene.
DR   neXtProt; NX_Q9NZJ5; -.
DR   OpenTargets; ENSG00000172071; -.
DR   Orphanet; 1667; Wolcott-Rallison syndrome.
DR   PharmGKB; PA27687; -.
DR   VEuPathDB; HostDB:ENSG00000172071; -.
DR   eggNOG; KOG1033; Eukaryota.
DR   GeneTree; ENSGT00940000158121; -.
DR   InParanoid; Q9NZJ5; -.
DR   OMA; QCQTDCK; -.
DR   OrthoDB; 1610714at2759; -.
DR   PhylomeDB; Q9NZJ5; -.
DR   TreeFam; TF101511; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; Q9NZJ5; -.
DR   Reactome; R-HSA-381042; PERK regulates gene expression.
DR   Reactome; R-HSA-9700645; ALK mutants bind TKIs.
DR   Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants.
DR   SignaLink; Q9NZJ5; -.
DR   SIGNOR; Q9NZJ5; -.
DR   BioGRID-ORCS; 9451; 21 hits in 1111 CRISPR screens.
DR   ChiTaRS; EIF2AK3; human.
DR   GeneWiki; EIF2AK3; -.
DR   GenomeRNAi; 9451; -.
DR   Pharos; Q9NZJ5; Tchem.
DR   PRO; PR:Q9NZJ5; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9NZJ5; protein.
DR   Bgee; ENSG00000172071; Expressed in body of pancreas and 197 other tissues.
DR   ExpressionAtlas; Q9NZJ5; baseline and differential.
DR   Genevisible; Q9NZJ5; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0004694; F:eukaryotic translation initiation factor 2alpha kinase activity; IDA:UniProtKB.
DR   GO; GO:0051879; F:Hsp90 protein binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004672; F:protein kinase activity; IBA:GO_Central.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; ISS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0030282; P:bone mineralization; ISS:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; ISS:UniProtKB.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; IMP:UniProtKB.
DR   GO; GO:0070417; P:cellular response to cold; IMP:UniProtKB.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0002063; P:chondrocyte development; ISS:UniProtKB.
DR   GO; GO:0036492; P:eiF2alpha phosphorylation in response to endoplasmic reticulum stress; IMP:UniProtKB.
DR   GO; GO:0031018; P:endocrine pancreas development; IMP:UniProtKB.
DR   GO; GO:0007029; P:endoplasmic reticulum organization; ISS:UniProtKB.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IDA:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; IDA:UniProtKB.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0031642; P:negative regulation of myelination; ISS:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; TAS:UniProtKB.
DR   GO; GO:0032055; P:negative regulation of translation in response to stress; IEA:Ensembl.
DR   GO; GO:0032057; P:negative regulation of translational initiation in response to stress; TAS:UniProtKB.
DR   GO; GO:0001503; P:ossification; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0036499; P:PERK-mediated unfolded protein response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0045943; P:positive regulation of transcription by RNA polymerase I; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0060734; P:regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation; ISS:UniProtKB.
DR   GO; GO:1902235; P:regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010998; P:regulation of translational initiation by eIF2 alpha phosphorylation; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IMP:BHF-UCL.
DR   GO; GO:1990737; P:response to manganese-induced endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; ISS:UniProtKB.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR011047; Quinoprotein_ADH-like_supfam.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   Pfam; PF00069; Pkinase; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50998; SSF50998; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; ATP-binding; Diabetes mellitus;
KW   Disease variant; Endoplasmic reticulum; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Signal; Stress response; Transferase;
KW   Translation regulation; Transmembrane; Transmembrane helix;
KW   Unfolded protein response.
FT   SIGNAL          1..29
FT                   /evidence="ECO:0000255"
FT   CHAIN           30..1116
FT                   /note="Eukaryotic translation initiation factor 2-alpha
FT                   kinase 3"
FT                   /id="PRO_0000024322"
FT   TOPO_DOM        30..514
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        515..535
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        536..1116
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          593..1077
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          77..101
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          550..571
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          841..863
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1090..1116
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        87..101
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        937
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         599..607
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         622
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         619
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:22169477"
FT   MOD_RES         715
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         982
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2B5"
FT   MOD_RES         1094
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   CARBOHYD        258
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         136
FT                   /note="S -> C (in dbSNP:rs867529)"
FT                   /evidence="ECO:0000269|PubMed:10932183,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_011409"
FT   VARIANT         166
FT                   /note="Q -> R (in dbSNP:rs13045)"
FT                   /evidence="ECO:0000269|PubMed:10026192,
FT                   ECO:0000269|PubMed:10677345, ECO:0000269|PubMed:15489334"
FT                   /id="VAR_011410"
FT   VARIANT         566
FT                   /note="D -> V (in dbSNP:rs55791823)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040477"
FT   VARIANT         588
FT                   /note="R -> Q (in WRS; dbSNP:rs121908569)"
FT                   /evidence="ECO:0000269|PubMed:10932183"
FT                   /id="VAR_011408"
FT   VARIANT         704
FT                   /note="A -> S (in dbSNP:rs1805165)"
FT                   /evidence="ECO:0000269|PubMed:10026192,
FT                   ECO:0000269|PubMed:10677345, ECO:0000269|PubMed:15489334"
FT                   /id="VAR_011411"
FT   VARIANT         716
FT                   /note="P -> L (in dbSNP:rs55861585)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040478"
FT   CONFLICT        14
FT                   /note="Missing (in Ref. 1; AAD19961, 2; AAF61199, 3;
FT                   AAF91480, 4; BAG37696 and 6; AAI26357)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        490
FT                   /note="N -> H (in Ref. 2; AAF61199)"
FT                   /evidence="ECO:0000305"
FT   STRAND          105..110
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          113..118
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   TURN            120..123
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          126..131
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          137..139
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          152..158
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          161..164
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          166..169
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          171..173
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   HELIX           178..182
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          193..204
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          207..209
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          215..217
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          220..222
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          237..248
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   TURN            250..252
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          255..267
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          308..310
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   TURN            314..317
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          321..323
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   TURN            324..326
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          339..346
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          349..352
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   HELIX           375..383
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          387..390
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   STRAND          392..398
FT                   /evidence="ECO:0007829|PDB:4YZS"
FT   HELIX           588..592
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   STRAND          593..602
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   STRAND          605..612
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   TURN            613..615
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   STRAND          618..625
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           630..644
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   STRAND          654..660
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   STRAND          883..889
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           896..901
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           906..908
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           911..930
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           940..942
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   STRAND          943..945
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   STRAND          951..953
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           993..996
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           1004..1018
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           1024..1035
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           1041..1046
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           1048..1057
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           1062..1064
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           1068..1072
FT                   /evidence="ECO:0007829|PDB:4X7K"
FT   HELIX           1075..1077
FT                   /evidence="ECO:0007829|PDB:4X7K"
SQ   SEQUENCE   1116 AA;  125216 MW;  95FEB5DAE8D3D452 CRC64;
     MERAISPGLL VRALLLLLLL LGLAARTVAA GRARGLPAPT AEAAFGLGAA AAPTSATRVP
     AAGAVAAAEV TVEDAEALPA AAGEQEPRGP EPDDETELRP RGRSLVIIST LDGRIAALDP
     ENHGKKQWDL DVGSGSLVSS SLSKPEVFGN KMIIPSLDGA LFQWDQDRES METVPFTVES
     LLESSYKFGD DVVLVGGKSL TTYGLSAYSG KVRYICSALG CRQWDSDEME QEEDILLLQR
     TQKTVRAVGP RSGNEKWNFS VGHFELRYIP DMETRAGFIE STFKPNENTE ESKIISDVEE
     QEAAIMDIVI KVSVADWKVM AFSKKGGHLE WEYQFCTPIA SAWLLKDGKV IPISLFDDTS
     YTSNDDVLED EEDIVEAARG ATENSVYLGM YRGQLYLQSS VRISEKFPSS PKALESVTNE
     NAIIPLPTIK WKPLIHSPSR TPVLVGSDEF DKCLSNDKFS HEEYSNGALS ILQYPYDNGY
     YLPYYKRERN KRSTQITVRF LDNPHYNKNI RKKDPVLLLH WWKEIVATIL FCIIATTFIV
     RRLFHPHPHR QRKESETQCQ TENKYDSVSG EANDSSWNDI KNSGYISRYL TDFEPIQCLG
     RGGFGVVFEA KNKVDDCNYA IKRIRLPNRE LAREKVMREV KALAKLEHPG IVRYFNAWLE
     APPEKWQEKM DEIWLKDEST DWPLSSPSPM DAPSVKIRRM DPFATKEHIE IIAPSPQRSR
     SFSVGISCDQ TSSSESQFSP LEFSGMDHED ISESVDAAYN LQDSCLTDCD VEDGTMDGND
     EGHSFELCPS EASPYVRSRE RTSSSIVFED SGCDNASSKE EPKTNRLHIG NHCANKLTAF
     KPTSSKSSSE ATLSISPPRP TTLSLDLTKN TTEKLQPSSP KVYLYIQMQL CRKENLKDWM
     NGRCTIEERE RSVCLHIFLQ IAEAVEFLHS KGLMHRDLKP SNIFFTMDDV VKVGDFGLVT
     AMDQDEEEQT VLTPMPAYAR HTGQVGTKLY MSPEQIHGNS YSHKVDIFSL GLILFELLYP
     FSTQMERVRT LTDVRNLKFP PLFTQKYPCE YVMVQDMLSP SPMERPEAIN IIENAVFEDL
     DFPGKTVLRQ RSRSLSSSGT KHSRQSNNSH SPLPSN
//
